APA (7th ed.) Citation

Sherif, B., Besse, B., Solomon, B., Bazhenova, L., Kim, D., Lin, J., . . . Drilon, A. (2023). PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1. Value in Health, 26(12), S484. https://doi.org/10.1016/j.jval.2023.09.2619

Chicago Style (17th ed.) Citation

Sherif, B., et al. "PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1." Value in Health 26, no. 12 (2023): S484. https://doi.org/10.1016/j.jval.2023.09.2619.

MLA (9th ed.) Citation

Sherif, B., et al. "PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1." Value in Health, vol. 26, no. 12, 2023, p. S484, https://doi.org/10.1016/j.jval.2023.09.2619.